[Aspects of neuroleptic depot therapy with special consideration of clinical experiences with the preoral depot preparation Penfluridol (R 16 341-Jannsen)].
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D004467:Economics; D005260:Female; D006801:Humans; D006846:Hydrocarbons, Halogenated / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy / Q000517:prevention & control; D012565:Schizophrenic Psychology; D012919:Social Behavior; D013997:Time Factors; D014050:Toluene / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D006846:Hydrocarbons, Halogenated; D010640:Phenothiazines; D010880:Piperidines; D014149:Tranquilizing Agents; D014050:Toluene
Aspekte der neuroleptischen Depottherapie unter besonderer Berücksichtigung klinischer Erfahrungen mit dem peroralen Depotpräparat Penfluridol (R 16 341 - Janssen)